Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
US commission recommends federal research revamp to avoid losing global biotech edge
(16h)
FTC outlines antitrust case against Edwards' $945M JenaValve acquisition
(17h)
AbbVie launches lab space award program for Quebec biotechs
(19h)
BioPharma Dive
Novartis wins approval to use SMA gene therapy in older patients
(20h)
Gilead scoops up a preclinical cancer program
(21h)
How do Big Pharma employees rate their CEOs?
(21h)
Endpoints News
Sanofi headquarters raided in broader French tax fraud investigation
(35m)
Kallyope scraps one of two mid-stage migraine drugs
(1h)
Otsuka’s anti-APRIL antibody gets FDA approval for kidney disease IgAN
(11h)
BioSpace
Are Animals Out? How NAMs Are Changing the Rules of the Game
(5h)
Budget Cuts Are Hobbling American Innovation
(6h)
Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight
(20h)
STAT News
Proposal to remove advanced nursing from list of ‘professional’ degrees is short-sighted and dangerous
(2h)
What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death?
(2h)
Why beagles are the No. 1 dog for medical research
(2h)
BioPharma Trend
Ginkgo Bioworks Launches Open-Source Pharmacology Framework for AI Drug Discovery
(6d)
Antheia and TAPI Announce Strategic Partnership to Scale Biosynthetic Pharmaceutical Manufacturing
(6d)
Terray Launches Experiment-Driven Machine Learning Platform for Small-Molecule Discovery
(1w)
Drug Channels
The Hidden Burdens of Cancer Care: When Insurers Override Doctors
(6d)
Drug Channels News Roundup, November 2025: PBM Revolution, Cuban’s Stelara Challenge, Express Scripts’ Price Games, U.S. Drug Spending Reality, and the AFP Reckoning
(1w)
The $700 Copay That Changed Everything
(2w)
European Biotechnology Magazine
Novo Nordisk’s semaglutide fails in Alzheimer’s
(2h)
Gilead acquires Sprint Bioscience TREX1 programme
(1d)
AGC Biologics to manufacture dual AAV therapies for AAVantgarde
(4d)
Drug Hunter
paltusotine
(18h)
October 2025 Patent Highlights
(4d)
October 2025
(5d)
Labiotech.EU
11 neuroscience biotech companies you should know about
(22h)
Six key obesity deals in 2025
(5d)
How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes
(5d)
Bio IT World
Follow the Money: Enveloped Delivery Vehicle Technology, Oral Medication for Inflammatory, Neurological Diseases, More
(1d)
Eli Lilly to Open Lab in Philadelphia, QIAGEN to Acquire Parse Biosciences, Novartis Expands to North Carolina
(2d)
Ginkgo Datapoints Launches Virtual Cell Pharmacology Initiative
(5d)
GEN News
Mapping the Neural Mechanism Behind Social Isolation Following Immune Challenge
(11h)
Backbone Potential: Actuate’s Elraglusib Shows Promise vs. Pancreatic Cancer
(12h)
Industry-Academia Collaboration Formed to Improve Cell and Gene Therapy Manufacturing
(12h)
Cure Today
Understanding Stage 1 Polycythemia Vera: What Every Patient Should Know
(14h)
How Vaccines Can Partner With Immunotherapy to Treat Lung Cancer
(15h)
FDA Approves Imfinzi Plus Chemo in GC/GEJC
(16h)
Contract Pharma
Sanofi and Regeneron’s Dupixent Approved in EU
(20h)
BioMed X, AbbVie Launch New Research Project Focused on Anhedonia
(22h)
The Future of Oral Solids
(1d)
Pharma Times
NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance
(23h)
FDA approves Keytruda and Keytruda Qlex with Padcev for bladder cancer
(1d)
Academy and Wellcome strengthen partnership with £27m agreement to boost UK health research
(2d)
Medcity News
FamilyWell Health Lands $8M to Grow Women’s Mental Health Support
(12h)
Boise’s Leading Sedation Dentistry Practices: A Comprehensive Guide
(12h)
Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble?
(12h)
Chemical & Engineering News
Nov. 25 Business Watch: Flexsys readies safer tire additive; Moderna halts trials of 3 mRNA drugs
(15h)
These archaea built a distinct genetic code to put pyrrolysine in proteins
(16h)
Reactions: Plastics recycling
(18h)
The Pharma Letter
Accelerated FDA approval for Otsuka’s Voyxact
(36m)
One thing the US Senate can agree on: It’s time to fix 340B
(1h)
TransCon CNP PDUFA delay likely a speed bump to approval
(1h)
Targeted Oncology
FDA Approves Durvalumab Plus FLOT in Early Stage Gastric/GEJ Cancers
(17h)
FDA Grants Fast Track Designation to AVZO-103 for Urothelial Cancer
(17h)
Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL
(18h)
MedWatch
Demant took market share among US veterans in October
(3h)
Analyst impressed by Novo Nordisk's new amycretin data
(21h)
Novo Nordisk's amycretin shows weight loss of up to 14.5%
(22h)
In The Pipeline
Alzheimer's Clinical Trial Results, Sadly Running True to Form
(14h)
Alcohol And Fructose, Tangled (and Untangled?)
(1d)
Reverse Proteolysis, Will You Look At That
(4d)
Pharmaphorum
Otsuka joins IgAN market with Voyxact approval in US
(48m)
Latest Medicare pricing cuts promise $12bn in savings
(1h)
Data sets up phase 3 trials for Novo's amycretin in diabetes
(22h)
Drug Discovery Weekly
10x Genomics launches international cancer research project
(20h)
Revolutionary therapy treats Hunter syndrome for first time
(20h)
DDW Highlights: 25 November 2025
(23h)
HIT Consultant
RapidAI Secures FDA Clearance for Five New Deep Clinical AI Modules, Expanding Enterprise Imaging Platform
(6h)
Fay and Withings Partner to Connect Health Data with Personalized Nutrition Counseling
(6h)
How Optimized Print Infrastructure Closes Compliance Gaps in Healthcare
(6h)
Insights: Pink Sheet
Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge
(2h)
US FDA Approves First Reformulated Rx Ranitidine, Five Years After Withdrawal
(9h)
As US FDA Turns: Can Makary, Prasad And Pazdur Make It Work?
(12h)
BioXconomy
J&J acquires Halda for $3.05bn to advance cancer treatment platform
(32m)
Curavit partners with Cenmed to enhance decentralized clinical trial logistics
(17h)
9amHealth launches ‘No-Barriers Bundle’ to expand employer access to obesity meds, virtual care
(17h)
BioCentury
Phase III comeback for Bayer’s asundexian in stroke prevention: Clinical Report
(11h)
Novartis hoping to lift SMA gene therapy sales with Itvisma approval
(12h)
Semaglutide’s Alzheimer’s miss: A case study in balancing ambition and evidence
(16h)